A053950 Stock Overview
Engages in the manufacture and sale of pharmaceutical, cosmetic, chemical, and health functional food products in South Korea, North America, and rest of Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kyung Nam Pharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩733.00 |
| 52 Week High | ₩1,790.00 |
| 52 Week Low | ₩540.00 |
| Beta | 0.089 |
| 1 Month Change | -4.68% |
| 3 Month Change | -6.51% |
| 1 Year Change | -55.06% |
| 3 Year Change | -86.53% |
| 5 Year Change | -92.67% |
| Change since IPO | -95.93% |
Recent News & Updates
Revenues Not Telling The Story For Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) After Shares Rise 29%
Nov 11
Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected
Aug 19Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price
May 21Recent updates
Revenues Not Telling The Story For Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) After Shares Rise 29%
Nov 11Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected
Aug 19Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price
May 21Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?
Mar 21Shareholder Returns
| A053950 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.0% | 1.5% | -1.6% |
| 1Y | -55.1% | 3.2% | -9.1% |
Return vs Industry: A053950 underperformed the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A053950 underperformed the KR Market which returned -9.1% over the past year.
Price Volatility
| A053950 volatility | |
|---|---|
| A053950 Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A053950's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A053950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 229 | Oh Hwan | www.kyungnampharm.co.kr |
Kyung Nam Pharm Co.,Ltd. engages in the manufacture and sale of pharmaceutical, cosmetic, chemical, and health functional food products in South Korea, North America, and rest of Asia. It also offers electronic, and agricultural and livestock products.
Kyung Nam Pharm Co.,Ltd. Fundamentals Summary
| A053950 fundamental statistics | |
|---|---|
| Market cap | ₩57.28b |
| Earnings (TTM) | -₩18.44b |
| Revenue (TTM) | ₩69.43b |
0.8x
P/S Ratio-3.1x
P/E RatioIs A053950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A053950 income statement (TTM) | |
|---|---|
| Revenue | ₩69.43b |
| Cost of Revenue | ₩51.03b |
| Gross Profit | ₩18.40b |
| Other Expenses | ₩36.84b |
| Earnings | -₩18.44b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -235.98 |
| Gross Margin | 26.50% |
| Net Profit Margin | -26.56% |
| Debt/Equity Ratio | 44.0% |
How did A053950 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 20:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kyung Nam Pharm Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Young Ok Kim | DAOL Investment & Securities Co., Ltd. |
| Joon-Geun Choi | Shinhan Investment Corp. |
| Kang Ho Oh | Shinhan Investment Corp. |